No Data
No Data
Viiv's Dovato as Effective as Gilead' Biktarvy for HIV but With Less Weight Gain
Gilead Sciences (GILD) Receives a Buy From TD Cowen
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Wells Fargo Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $78
Analysts' Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)
Gilead Sciences: A Balanced Outlook With Steady HIV Performance and Oncology Challenges Justifying a Hold Rating
Supermengg :![+1 👍](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f44d.png)
103397071 : good
73958256 : translate
Paul Anthony : visit Singapore coming up
Paul Anthony : for young people with this learn about the best person in charge A1 Amen together![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f.png)
![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f.png)
![people_hugging 🫂](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1fac2.png)